Colorectal surgery in elderly population

Introduction: With the rising number of elderly patients and increasing incidence of colorectal cancer, management of geriatric patients has become the forefront of colorectal surgery. Objectives: This study aimed to investigate the short-term surgical outcomes following colorectal resection in elderly patients. Materials and methods: A total of 464 patients who underwent surgical resection for colorectal tumor between 2013 and 2017 were included. The patients were divided into elderly (≥75 years) and young (<75 years) group. The clinicopathological data of the patients were reviewed retrospectively. Results: The elderly group constituted 30% of study population. More patients in elderly group underwent Hartmann procedure (p=0.02) and right hemicolectomy (p=0.029), and younger patients more often received low anterior resection (p=0.027). The surgical procedure took a shorter time in elderly group (p<0.01) but they stayed in the hospital one day longer (p=0.023). Postoperative complications and mortality tended to be higher in seniors (p=0.088). The younger patients showed a tendency towards a higher rate of distant metastases (p=0.053). Seniors received fewer preoperative chemoradiation than the young group (p=0.014). Conclusion: Older persons constitute one-third of patients treated electively in colorectal departments. Colorectal surgery in geriatric patients is associated with a prolonged hospital stay and a higher potential for complications and mortality.

Download Full-text

Can a conventional schedule of radiation therapy be administered to elderly patients with glioblastoma multiforme?

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.12516 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 12516-12516

Author(s):

S. Manfrida ◽

G. R. D’Agostino ◽

C. Anile ◽

G. Mantini ◽

G. Colicchio ◽

...

Keyword(s):

Glioblastoma Multiforme ◽

Elderly Patients ◽

Conformal Radiotherapy ◽

Residual Tumor ◽

The Elderly ◽

Elderly Group ◽

Female Ratio ◽

Younger Patients ◽

Tumor Bed ◽

Grade 3

12516 Background: We retrospectively evaluate the tolerance and the efficacy of a conventional schedule of radiotherapy in elderly patients with glioblastoma multiforme (GBM). Methods: Eighty-three consecutive patients affected by glioblastomas were treated between 2001 and 2006. We divided our series in two groups: patients under 65 years (n=52) and patients ≥ 65 years old (n=31). In the elderly group, median age was 68 years (range, 65–80). 17 patients (54,8%) were female, 14 male (45,2%); 20 patients (64,5%) <70 years, 11 patients (35,5%) ≥70 years. Among the younger patients, median age was 51 years (range 25–64), male/female ratio 32/20 (61.5%/38.5%).Twenty-seven out of 31 elderly patients (87,1%) were treated with conformal radiotherapy (CRT, 5940 cGy, 180 cGy/day; CTV2: tumor bed + residual tumor if present + oedema, 3960 cGy; CTV1: tumor bed + residual tumor if present + margins, 1980 cGy). Four out of 31 patients received an intensification dose of xxxx cGy by stereotactic conformal radiotherapy (SRT, 12,9%); among the younger patients, 25/52 were treated with CRT (48,1%) and 27/52 with SRT (51,9%). Concomitant and adjuvant chemotherapy was administered by temozolomide (TMZ).Toxicity was evaluated according to RTOG score. Survival analysis were performed using Kaplan-Meier method and log-rank testing was used for comparison of groups. Results: In the elderly group, neurological acute toxicity was observed in 6/31 patients (19,4%), with grade 3 in two patients. In the under 65 group, 5/52 patients (9,6%) had neurotoxicity (Grade 3 in two patients).This difference was not statistically different.At a median follow-up period of 28 months (range, 3–61), median progression-free survival (PFS) was 11 months in the ≥65 group and 10 months in the under 65 group; median overall survival (OS) was respectively 17 months and 22 months. 1- year survival was respectively 77.6% and 74.5%. Conclusions: In our analysis age did not seem to be a limiting factor in the choice of the therapeutic strategy for patients with glioblastoma multiforme. No significant financial relationships to disclose.

Download Full-text

Hemifacial Spasm: Comparison of Results between Patients Older and Younger than 70 Years Operated on with Microvascular Decompression

Journal of Neurological Surgery Part A Central European Neurosurgery ◽

10.1055/s-0040-1721018 ◽

2021 ◽

Author(s):

Hua Zhao ◽

Jin Zhu ◽

Yin-da Tang ◽

Lin Shen ◽

Shi-ting Li

Keyword(s):

Elderly Patients ◽

Hemifacial Spasm ◽

Microvascular Decompression ◽

Facial Palsy ◽

The Elderly ◽

Elderly Group ◽

Effective Treatment Option ◽

Younger Patients ◽

Significant Difference ◽

Csf Leakage

Abstract Objective The aim of the present study was to evaluate the efficacy and safety of microvascular decompression (MVD) for primary hemifacial spasm (HFS) in patients aged ≥70 years and to compare the outcome with a control cohort of younger patients(<70 years). Methods In this retrospective study, subjects were divided into two groups: an elderly group (patients who were ≥70 years) and a younger group. We compared demographic and clinical data, surgical outcome, MVD-related complications, and duration of operation and hospitalization after MVD between the two groups. Results At a mean follow-up of 32 ± 4.2 months, 188 elderly patients (90.4%) reported an effective outcome without need for any medication versus 379 (91.1%) of the younger cohort. There was no mortality in both cohorts. The prevalence of delayed facial palsy was 4.8% in the elderly group and 4.1% in the younger group. One (0.5%) patient in the elderly group and 3 (0.7%) patients in the younger group suffered cerebrospinal fluid (CSF) leakage. There was no significant difference between the two groups in terms of MVD-related complications, such as delayed facial palsy, hearing impairment, CSF leakage, and hematoma. Conclusions MVD is an effective treatment option in elderly patients with HFS as well as in younger patients. Age itself seems to be no relevant contraindication or, alternatively, risk factor regarding MVD.

Download Full-text

Endoscopic endonasal transsphenoidal surgery in elderly patients with pituitary adenomas

Journal of Neurosurgery ◽

10.3171/2014.10.jns14372 ◽

2015 ◽

Vol 123 (1) ◽

pp. 31-38 ◽

Cited By ~ 32

Author(s):

Jackson A. Gondim ◽

João Paulo Almeida ◽

Lucas Alverne F. de Albuquerque ◽

Erika Gomes ◽

Michele Schops ◽

...

Keyword(s):

Surgical Treatment ◽

Elderly Patients ◽

Transsphenoidal Surgery ◽

Clinical Status ◽

The Elderly ◽

Elderly Group ◽

Complication Rates ◽

Endoscopic Transsphenoidal Surgery ◽

Younger Patients ◽

Significant Difference

OBJECT With the increase in the average life expectancy, medical care of elderly patients with symptomatic pituitary adenoma (PA) will continue to grow. Little information exists in the literature about the surgical treatment of these patients. The aim of this study was to present the results of a single pituitary center in the surgical treatment of PAs in patients > 70 years of age. METHODS In this retrospective study, 55 consecutive elderly patients (age ≥ 70 years) with nonfunctioning PAs underwent endoscopic transsphenoidal surgery at the General Hospital of Fortaleza, Brazil, between May 2000 and December 2012. The clinical and radiological results in this group were compared with 2 groups of younger patients: < 60 years (n = 289) and 60–69 years old (n = 30). RESULTS Fifty-five patients ≥ 70 years of age (average age 72.5 years, range 70–84 years) underwent endoscopic surgery for treatment of PAs. The mean follow-up period was 50 months (range 12–144 months). The most common symptoms were visual impairment in 38 (69%) patients, headache in 16 (29%) patients, and complete ophthalmoplegia in 6 (10.9%). Elderly patients presented a higher incidence of ophthalmoplegia (p = 0.032) and a lower frequency of pituitary apoplexy before surgery (p < 0.05). Tumors with cavernous sinus invasion were treated surgically less frequently than in younger patients. Although patients with an American Society of Anesthesiologists score of 3 were more common in the elderly group (p < 0.05), no significant difference regarding surgical time, extent of resection, and hospitalization were observed. Elderly patients presented with more complications than patients < 60 years (32.7% vs 10%, p < 0.05). Complications observed in the elderly group included 5 CSF leaks (9%), 2 permanent diabetes insipidus cases (3.6%), 4 postoperative refractory hypertension cases (7.2%), 1 myocardial ischemia (1.8%), and 1 death (1.8%). Postoperative new anterior pituitary deficit was more common in the younger group (< 60 years old: 17.7%) than in the elderly (≥ 70 years old: 12.7%); however, there was no statistical difference. CONCLUSIONS Endoscopic transsphenoidal surgery for elderly patients with PAs may be associated with higher complication rates, especially secondary to early transitory complications, when compared with surgery performed in younger patients. Although the worst preoperative clinical status might be observed in this group, age alone is not associated with a worst final prognosis after endoscopic removal of nonfunctioning PAs.

Download Full-text

Clinical presentation of urolithiasis in older and younger population

Archivio Italiano di Urologia e Andrologia ◽

10.4081/aiua.2014.4.249 ◽

2014 ◽

Vol 86 (4) ◽

pp. 249 ◽

Cited By ~ 4

Author(s):

Murat Dursun ◽

Emin Ozbek ◽

Alper Otunctemur ◽

Suleyman Sahin ◽

Suleyman Sami Cakir

Keyword(s):

Heart Disease ◽

Elderly Patients ◽

Average Length ◽

The Elderly ◽

Stone Disease ◽

Elderly Group ◽

Ureteral Stones ◽

Chronic Obstructive ◽

Younger Patients ◽

The Difference

Aim of the study: We compared stone size, localization, complaint at the time of applying, comorbidity, treatment and complications between older (60 years of age and older) and younger patients with urolithiasis (59 years of age and younger). Materials and Methods: We retrospectively reviewed the records of 950 consecutive patients who presented to our clinic and underwent surgery for urolithiasis from January 2007 to March 2012. The patients were divided into two groups: patients ≥ 60 years an patients < 60 years. Results: There were 174 men and 61 women in elderly group, 528 men and 187 women in younger group. Ureteral stones were found more often in the younger group compared to elderly patients (p < 0.05). Conversely, bladder stone was more frequent in the elderly group. In the elderly group comorbidities are more frequent (diabetes mellitus, hypertension, ischemic heart disease, congestive heart disease, osteoarthritis and chronic obstructive lung). Patients ≥ 60 years significantly had larger kidney and bladder stones compared the younger, but ureteral stone sizes were not statistically different between the two groups. Older patients had a higher postoperative complication rate than younger patients (16% versus 3%, p < 0.05) although postoperative complications (e.g. urinary retention, cardiac dysrythmia, fever, constipation) were not serious and resolved with medical treatment. The average length of stay in hospital was longer in the elderly group, but the difference was not statistically significant. Conclusions: Elderly patients with urolithiasis usually have larger and more complex stone disease, more comorbidities and atypical presentation.

Download Full-text

551 INCREASED POSTOPERATIVE MORBIDITY AFTER TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER IN ELDERLY PATIENTS

Diseases of the Esophagus ◽

10.1093/dote/doab052.551 ◽

2021 ◽

Vol 34 (Supplement_1) ◽

Author(s):

Nikolaj Baranov ◽

Frans Van Workum ◽

Camiel Rosman

Keyword(s):

Minimally Invasive ◽

Elderly Patients ◽

Minimally Invasive Esophagectomy ◽

Age Groups ◽

The Elderly ◽

Elderly Group ◽

Younger Patients ◽

Invasive Esophagectomy ◽

Outcome Parameters ◽

Increased Risk

Abstract The incidence of elderly patients with esophageal cancer is increasing. The aim of this study is to compare postoperative outcomes after esophagectomy between elderly patients and younger patients and to compare outcomes after totally minimally invasive esophagectomy (TMIE) and open esophagectomy (OE) in these age groups. Methods Data was retrieved from the Dutch Upper Gastrointestinal Cancer Audit (DUCA), a national surgical outcome registry. The primary outcome parameter was severe complications, defined as Clavien Dindo ≥3. Secondary outcome parameters were postoperative complications, reintervention rate, length of hospital stay and mortality. Outcome parameters were compared between patients aged ≥75 years and < 75 years and between TMIE and OE in these age groups. We adjusted for the following casemix parameters: gender, Charlson Co-morbidity Index score ASA score and neoadjuvant therapy. A sensitivity analysis was performed with different age groups: <65, 65–69, 70–74, 75–79 and ≥ 80 years. Results Of all 5539 included patients 14.0% were aged ≥75 years and 86.0% were aged <75 years. Severe complications were observed more frequently in the elderly group compared to the younger group (RR = 1.15 [1.04–1.27], p = 0.007). Interestingly, there was an increased risk of severe complications after TMIE in both the elderly group (RR = 1.50 [1.19–1.90], p = 0.001) and the younger group (RR = 1.41 [1.28–1.56], p < 0.001). No difference in mortality between TMIE and OE was found. Sensitivity analyses of TMIE compared to OE across all age groups showed increased risk of severe complications. Adjustment for casemix for all analysis did not change the results. Conclusion Severe complications after esophagectomy occur more frequently in elderly compared to younger patients. TMIE in elderly patients did not result in less morbidity and was in fact associated with more severe complications compared to OE across all age groups, which may be due to a learning curve effect.

Download Full-text

P1343DOES “FISTULA FIRST” FITS TO ELDERLY?

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p1343 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Valerio Patricia ◽

Elsa Soares ◽

Ana Farinha ◽

Teresa Furtado ◽

Catarina Abrantes ◽

...

Keyword(s):

Elderly Patients ◽

Clinical Outcomes ◽

Median Survival ◽

The Elderly ◽

Elderly Group ◽

Disease Etiology ◽

Younger Patients ◽

Surgical Interventions ◽

Comorbidity Burden ◽

The Impact

Abstract Background and Aims The incident patients on hemodialysis (HD) are becoming older. However, the optimal type of initial permanent vascular access (VA) among the elderly is controversial. Patient comorbidities and life expectancy are important considerations in whether to place an arteriovenous fistula (AVF) or graft (AVG). We design an observational study to compare clinical outcomes of elderly (≥65 year old) versus younger patients, who underwent for first VA placement before initiation of renal replacement therapy, between January 2014 and December 2018. Method We evaluated successful use of VA, requirement of surgical interventions before successful use, VA in use after the first and third months on HD and clinical outcomes, until December 2019. The comorbidity burden was calculated through age-adjusted Charlson Comorbidity Index (aCCI). We also evaluated the impact of comorbidity burden on the VA type on HD start and mortality after HD initiation. Results We identified 252 predialysis patients who underwent for VA placement in our center. We created two groups based on age at the time of VA placement: there were 199 (79,0%) with age ≥ 65 years (the elderly group), and 53 (21,0%) younger patients. The elderly group presented a mean age of 76,3 ± 6,4 (maximum of 92) years on first VA placement; in the younger group, the mean age was 54,5 ± 9,1 (minimum of 26) years. The following analysis are presented for elderly versus younger group. On both groups there were a predominance of male gender (66,8%; 73,6%; p=0,498) and caucasian race (95,0%; 88,7%; p=0,193). At time of referral for AV placement, both groups presented similar mean estimated glomerular filtration rate by CKD-EPI equation (11,7 ± 3,2; 11,2 ± 3,2 mL/Kg/1,72m2; p=0,391). Elderly group presented a significant higher aCCI (7,3 ± 1,74; 9,0 ± 1,9; p<0,001). The groups were also different in smoking status (6,0%; 30,8%; p<0,001). There were no differences on kidney disease etiology between groups, with diabetes being the most prevalent (23,1%; 24,5%; p=0,856). For all patients, the first VA placed was AVF. Only two patient placed an AVG on second and third vascular accesses. The median number of VA placed were similar between the two groups [1,0 (1 to 4); 1,0 (1 to 2); p= 0,811], likewise the occurrence of early complications (9,5%; 5,7%; p=0,583) and the need for surgical interventions (46,7%; 47,2%; p=1,000). In both groups, the majority of patients started HD (80,4%; 90,6%; p=0,103), with similar successful use of the VA (68,1%; 75,0%; p=0,474). In multivariate logistic regression, proteinuria (measured at time of referral for AV placement) and heart failure (HF) were predictors to HD initiation through a central venous catheter (CVC). This model classified correctly 74,9% of cases, with an HF odds ratio (OR) of 4,149 [confident interval (CI) of 1,721 to 10,000] and a proteinuria OR of 1,148 (CI: 1,047 to 1,259). After the first month on HD, 34,8% of elderly patients needed a CVC, a number significantly different from the younger group (15,9%; p=0,023). The same result was observed after the third month (22,2%; 7,1%; p=0,028). During the time of follow-up, the mortality rate was higher in the elderly group who started HD (log Rank test = 0,004), with a median survival of 29,3 (0,1 to 89,8) months, when compared to the younger group [median survival of 38,3 (0,1 to 76,9) months]. Conclusion There were no difference in the kind of VA on HD start (definitive VA versus CVC) between the two groups. However, elderly patients presented more fistula failure in the first three months after HD initiation. The need of CVC due to nonfunctioning AVF on the first and three months after HD initiation was higher in the elderly. The analysis of the patients who started HD showed that the elderly group presented a significant reduced survival when compared to the youngest patients.

Download Full-text

First Line B+R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real-World Experience

Blood ◽

10.1182/blood-2021-144888 ◽

2021 ◽

Vol 138 (Supplement 1) ◽

pp. 4519-4519

Author(s):

Rouslan Kotchetkov ◽

David Susman ◽

Lauren M. Gerard ◽

Erica Dimaria ◽

Derek Nay ◽

...

Keyword(s):

Adverse Events ◽

Elderly Patients ◽

Real World ◽

Renal Carcinoma ◽

Cell Lymphoma ◽

The Elderly ◽

Elderly Group ◽

First Line ◽

Younger Patients ◽

Mantle Cell

Abstract Background: Bendamustine plus rituximab (B+R) was established as a preferred first-line therapy for indolent non-Hodgkin's lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on the performance of this combination in the real-world setting in elderly patients are available to date. Methods: A retrospective review of adult patients over 70 years (elderly) vs younger (<70 years) with iNHL and MCL who received first-line B+R at our institution from June 2013 to January 2021. We assessed safety, acute and late toxicity, and efficacy of B+R in elderly patients, compared to younger group. Results: Among 201 assessed patients, 133 were elderly (mean age 77.9 years) and 88 younger (mean age 61.1 years) at time of B+R initiation. Baseline patient characteristics are presented in Table 1. There were more MCL in the elderly group: 20.3% vs 3.2% in the younger group. Significantly more patients in the elderly group had history of second malignancy. Prostate, breast, colon, and bladder cancer were more common in elderly, and lymphoid and thyroid in younger groups. Bulky lymphadenopathy, cytopenia, and constitutional symptoms were the most common indications for B+R initiation both in elderly (74.4%) and younger (79.26%) patients. Median number of B+R cycles was 6 for both groups. Mean dose of bendamustine received was 83.6 mg/m 2 in the elderly vs 88 mg/m 2 in the younger groups (p=0.0001). Full doses of bendamustine were given in 54% of elderly patients as compared to 79.5% younger patients. Treatment was delayed in 54% of the elderly and 43.2% of the younger patients. The mean delay time was similar in both groups: 20.1 [7-147] vs 17.1 [7-35 days]. The number of adverse events (AE) per patient was similar between the groups across each cycle (Table 2). Rituximab-associated infusion reactions were the most common adverse events in both groups. One patient in younger group developed prolonged neutropenia, lasting over 15 months. G-CSF support received 12.4% elderly and 22.7% younger patients. Nine patients (8%) in elderly and six patients (6.8%) in younger group (p=0.7604) developed transformed aggressive B-Cell lymphoma. Thirteen patients (11.5%) in elderly and five patients (5.7%) in younger group (p=0.1530) had secondary malignancies. Melanoma, metastatic squamous cell and renal carcinoma were more common in elderly group. Younger patients had metastatic squamous cell carcinoma and renal carcinoma, Kaposi sarcoma, MDS and thyroid cancer. Overall response rate was 91.2% in elderly group vs 98.9% in younger group, including complete remission in 71.7% vs 84.1%. Median follow-up was 42 months [4.0-97.0]. Although median overall survival (OS) was not reached in both groups, it was shorter in elderly compared to younger group (HR 0.24, CI 0.14-0.42, p<0.0001) (Figure 1A). Relapse rate was 10.6% in elderly vs 4.5% in younger groups. Median event free survival (defined as time between the first treatment and one of the following events: progressive disease, relapse or death) for follicular lymphoma, the most common histological subgroup in both cohorts, was shorter in the elderly compared to younger groups (82.0 months vs not yet reached; HR 0.19, CI 0.05-0.71, p=0.0385) (Figure 1B) Conclusion: In the real-world setting elderly patients had more advanced and high-risk disease, as well as higher ECOG status. B+R was associated with greater dose reduction and treatment delays. Adverse events profile and incidence did not differ significantly from the younger group. Response rates were lower, but relapse rate was higher in elderly patients. OS was inferior in elderly patients as compared to the younger group, due to higher rate of relapse and secondary malignancies. Figure 1 Figure 1. Disclosures Prica: Astra-Zeneca: Honoraria; Kite Gilead: Honoraria.

Download Full-text

ACUTE KIDNEY INJURY IN ELDERLY PATIENTS

Wiadomości Lekarskie ◽

10.36740/wlek201908109 ◽

2019 ◽

Vol 72 (8) ◽

pp. 1466-1472

Author(s):

Grażyna Kobus ◽

Jolanta Małyszko ◽

Hanna Bachórzewska-Gajewska

Keyword(s):

Acute Kidney Injury ◽

Renal Failure ◽

Acute Renal Failure ◽

Elderly Patients ◽

Older Patients ◽

Age Groups ◽

Kidney Injury ◽

The Elderly ◽

Younger Patients ◽

Common Cause

Introduction: In the elderly, impairment of kidney function occurs. Renal diseases overlap with anatomic and functional changes related to age-related involutionary processes. Mortality among patients with acute renal injury is approximately 50%, despite advances in treatment and diagnosis of AKI. The aim: To assess the incidence of acute kidney injury in elderly patients and to analyze the causes of acute renal failure depending on age. Materials and methods: A retrospective analysis included medical documentation of patients hospitalized in the Nephrology Clinic during the 6-month period. During this period 452 patients were hospitalized in the clinic. A group of 77 patients with acute renal failure as a reason for hospitalization was included in the study. Results: The prerenal form was the most common cause of AKI in both age groups. In both age groups, the most common cause was dehydration; in the group of patients up to 65 years of age, dehydration was 29.17%; in the group of people over 65 years - 43.39%. Renal replacement therapy in patients with AKI was used in 14.29% of patients. In the group of patients up to 65 years of age hemodialysis was 16.67% and above 65 years of age. -13.21% of patients. The average creatinine level in the group of younger patients at admission was 5.16 ± 3.71 mg / dl, in the group of older patients 3.14 ± 1.63 mg / dl. The size of glomerular filtration GFR in the group of younger patients at admission was 21.14 ± 19.54 ml / min, in the group of older patients 23.34 ± 13.33 ml / min. Conclusions: The main cause of acute kidney injury regardless of the age group was dehydration. Due to the high percentage of AKI in the elderly, this group requires more preventive action, not only in the hospital but also at home.

Download Full-text

Safety of High-Dose Dabigatran in Elderly and Younger Patients with a Low Bleeding Risk: A Prospective Observational Study

Cardiology ◽

10.1159/000516368 ◽

2021 ◽

pp. 1-5

Author(s):

Aharon Erez ◽

Gregory Golovchiner ◽

Robert Klempfner ◽

Ehud Kadmon ◽

Gustavo Ruben Goldenberg ◽

...

Keyword(s):

Observational Study ◽

Elderly Patients ◽

Prospective Observational Study ◽

Bleeding Risk ◽

The Elderly ◽

High Dose ◽

World Population ◽

Younger Patients ◽

End Point

Introduction: In patients with atrial fibrillation (AF) at risk for stroke, dabigatran 150 mg twice a day (DE150) is superior to warfarin for stroke prevention. However, there is paucity of data with respect to bleeding risk at this dose in elderly patients (≥75 years). We aimed to evaluate the safety of DE150 in comparison to warfarin in a real-world population with AF and low bleeding risk (HAS-BLED score ≤2). Methods: In this prospective observational study, 754 consecutive patients with AF and HAS-BLED score ≤2 were included. We compared outcome of elderly patients (age ≥75 tears) to younger patients (age <75 years). The primary end point was the combined incidence of all-cause mortality, stroke, systemic emboli, and major bleeding event during a mean follow-up of 1 year. Results: There were 230 (30%) elderly patients, 151 patients were treated with warfarin, and 79 were treated with DE150. Fifty-two patients experienced the primary endpoint during the 1-year follow-up. Among the elderly, at 1-year of follow-up, the cumulative event rate of the combined endpoint in the DE150 and warfarin was 8.9 and 15.9% respectively (p = 0.14). After adjustment for age and gender, patients who were treated with DE150 had a nonsignificant difference in the risk for the combined end point as patients treated with warfarin both among the elderly and among the younger population (HR 0.58, 95% C.I = 0.25–1.39 and HR = 1.12, 95% C.I 0.62–2.00, respectively [p for age-group-by-treatment interaction = 0.83). Conclusions: Our results suggest that Dabigatran 150 mg twice a day can be safely used among elderly AF patients with low bleeding risk.

Download Full-text

Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study

BMC Gastroenterology ◽

10.1186/s12876-021-01791-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Hiroyuki Hisada ◽

Yu Takahashi ◽

Manabu Kubota ◽

Haruhisa Shimura ◽

Ei Itobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Prognostic Factors ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Carcinoembryonic Antigen ◽

Prognostic Nutritional Index ◽

Hazard Ratio ◽

Elderly Group ◽

Younger Patients ◽

Nutritional Index

Abstract Background Colorectal cancer (CRC) is one of the most common cancers in the world. The number of elderly patients with CRC increases due to aging of the population. There are few studies that examined chemotherapy and prognostic factors in metastatic colorectal cancer (mCRC) patients aged ≥ 80 years. We assessed the efficacy of chemotherapy and prognostic factors among patients with mCRC aged ≥ 80 years. Methods We retrospectively analyzed clinical and laboratory findings of 987 patients newly diagnosed with CRC at Asahi General Hospital (Chiba, Japan) between January 2012 and December 2016. The Kaplan–Meier method was used for the overall survival (OS) and the log-rank test was used to identify difference between patients. A multivariate Cox proportional hazard regression analysis was performed to determine the hazard ratios and 95% confidence intervals (CIs) of prognostic factors among super-elderly patients. Results In total, 260 patients were diagnosed with mCRC (super-elderly group: n = 43, aged ≥ 80 years and younger group, n = 217, aged < 80 years). The performance status and nutritional status were worse in the super-elderly group than in the younger group. The OS of super-elderly patients who received chemotherapy was worse than that of younger patients (18.5 vs. 28.8 months; P = 0.052), although the difference was not significant. The OS of patients who received chemotherapy tended to be longer than that of those who did not; however, there were no significant differences in OS in the super-elderly group (18.5 vs. 8.4 months P = 0.33). Multivariate analysis revealed that carcinoembryonic antigen levels ≥ 5 ng/mL (hazard ratio: 2.27; 95% CI 1.09–4.74; P = 0.03) and prognostic nutritional index ≤ 35 (hazard ratio: 8.57; 95% CI 2.63–27.9; P = 0.0003) were independently associated with poor OS in the super-elderly group. Conclusions Patients with mCRC aged ≥ 80 years had lower OS than younger patients even though they received chemotherapy. Carcinoembryonic antigen and prognostic nutritional index were independent prognostic factors in super-elderly patients with mCRC, but chemotherapy was not. Trial registration: retrospectively registered.

Download Full-text